Cargando…

Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials

BACKGROUND: Evidence that chemotherapy improves survival and quality of life in patients with stage IIIB & IV non small cell lung cancer (NSCLC) is based on large randomized controlled trials. The purpose of this study was to determine eligibility of patients with advanced NSCLC for major chemot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vardy, Janette, Dadasovich, Ryan, Beale, Philip, Boyer, Michael, Clarke, Stephen J
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683856/ https://www.ncbi.nlm.nih.gov/pubmed/19402889 http://dx.doi.org/10.1186/1471-2407-9-130

Ejemplares similares

Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial
por: Teng, Christina, et al.
Publicado: (2022)

The impact of physical activity on fatigue and quality of life in lung cancer patients: a randomised controlled trial protocol
por: Dhillon, Haryana M, et al.
Publicado: (2012)

Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer
por: Baka, S, et al.
Publicado: (2008)

Barriers to non-small cell lung cancer trial eligibility
por: Hardesty, Jeffrey J., et al.
Publicado: (2017)

Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study
por: Boys, Emma, et al.
Publicado: (2023)

Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review
por: Hotta, Katsuyuki, et al.
Publicado: (2011)

A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer
por: Si, Xiaoyan, et al.
Publicado: (2020)

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
por: Zhao, Ze-Rui, et al.
Publicado: (2021)

The effect of prior cancer on non‐small cell lung cancer trial eligibility
por: Herman, Michael, et al.
Publicado: (2021)

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
por: Negoro, S, et al.
Publicado: (2003)

Long-term outcome of radiological-guided insertion of implanted central venous access port devices (CVAPD) for the delivery of chemotherapy in cancer patients: institutional experience and review of the literature
por: Vardy, J, et al.
Publicado: (2004)

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)
por: Wang, Zhijie, et al.
Publicado: (2023)

Whole brain radiotherapy after local treatment of brain metastases in melanoma patients - a randomised phase III trial
por: Fogarty, Gerald, et al.
Publicado: (2011)

Trends in phase III randomized controlled clinical trials on the treatment of advanced non‐small‐cell lung cancer
por: Fernández‐López, Cristina, et al.
Publicado: (2016)

“POLAR-izing” Findings From Trials of Neuroprotection for Oxaliplatin Neuropathy
por: Teng, Christina, et al.
Publicado: (2022)

First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial
por: Wachters, F M, et al.
Publicado: (2003)

Systematic analysis of design and stratification for phase III trials in first‐line advanced non‐small cell lung cancer
por: Komiya, Takefumi, et al.
Publicado: (2015)

Therapeutic Options for Patients who are not Eligible for Intensive Chemotherapy
por: Estey, Elihu
Publicado: (2013)

Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer
por: Vardy, Janette, et al.
Publicado: (2013)

Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)
por: Seckl, Michael J., et al.
Publicado: (2017)

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial
por: Jiang, Tao, et al.
Publicado: (2022)

Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide
por: Young, R J, et al.
Publicado: (2012)

Patient Eligibility and Results for Brain Metastasis in Phase 3 Trials of Advanced Breast Cancer: A Scoping Review
por: Duchnowska, Renata, et al.
Publicado: (2021)

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers
por: Smyth, Elizabeth C, et al.
Publicado: (2021)

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
por: Schuler, M., et al.
Publicado: (2016)

Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials
por: Zhang, Yiliang, et al.
Publicado: (2013)

Efficacy and safety of docetaxel for advanced non-small-cell lung cancer: a meta-analysis of Phase III randomized controlled trials
por: He, Xuan, et al.
Publicado: (2015)

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
por: Yang, J J, et al.
Publicado: (2017)

Identification of patients with locally advanced rectal cancer eligible for neoadjuvant chemotherapy alone: Results of a retrospective study
por: Han, Yi‐min, et al.
Publicado: (2023)

Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer
por: Bondarenko, Igor M, et al.
Publicado: (2015)

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
por: Novello, Silvia, et al.
Publicado: (2023)

Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study
por: Ramalingam, Suresh S., et al.
Publicado: (2021)

Chemotherapy in non-small cell lung cancer: opportunities for advancement
por: Akhtari, Mani, et al.
Publicado: (2016)

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
por: Jackson, Graham H., et al.
Publicado: (2021)

Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I–II trial
por: Stathopoulos, G P, et al.
Publicado: (2005)

Acute phase reaction during chemotherapy in small cell lung cancer.
por: Milroy, R., et al.
Publicado: (1989)

Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent Chemoradiation
por: Li, Jing, et al.
Publicado: (2020)

Screening for cognitive symptoms among cancer patients during chemotherapy: Sensitivity and specificity of a single item self‐report cognitive change score
por: Fardell, Joanna E., et al.
Publicado: (2022)

Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Administration Rates
por: Eichkorn, Tanja, et al.
Publicado: (2020)

Eligibility for Bevacizumab as an Independent Prognostic Factor for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study
por: Takagi, Yusuke, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_a86qrhshhvcam8ol5apg0nr20m